# Filing Detail

Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-121445
Filing Date
2024-11-05
Accepted
2024-11-05 16:05:21
Documents
59
Period of Report
2024-09-30

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 10-Q | stok-20240930.htm iXBRL | 10-Q | 1938033
2 | EX-31.1 | stok-ex31_1.htm | EX-31.1 | 16202
3 | EX-31.2 | stok-ex31_2.htm | EX-31.2 | 16012
4 | EX-32.1 | stok-ex32_1.htm | EX-32.1 | 8104
5 | EX-32.2 | stok-ex32_2.htm | EX-32.2 | 8886
| Complete submission text file | 0000950170-24-121445.txt |  | 6209106

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
6 | XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT | stok-20240930.xsd | EX-101.SCH | 735996
61 | EXTRACTED XBRL INSTANCE DOCUMENT | stok-20240930_htm.xml | XML | 885236

Mailing Address 45 WIGGINS AVENUE BEDFORD MA 01730
Business Address 45 WIGGINS AVENUE BEDFORD MA 01730 781-430-8200
Stoke Therapeutics, Inc. (Filer) CIK: 0001623526 (see all company filings)

EIN.: 471144582 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38938 | Film No.: 241427417
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)